These observations are consistent with the current clinical trial results showing that CRP inhibitors can reduce plasma CRP levels by ~80% in normal subjects, as well as, endotoxin challenged and atrial fibrillation patients while other key cytokines, signs, and symptoms remained entirely unchanged in the endotoxin challenged subjects (Graham, M. personal communications). This evidence concerns the gene CRP and atrial fibrillation.